10-Q: Black Hawk Acquisition Corp. Reports Q2 2025 Results, Advances Vesicor Merger Amidst Going Concern Doubts

Black Hawk Acquisition Corporation, a SPAC, announced its second-quarter 2025 financial results, highlighted by increased net income and progress on its proposed business combination with Vesicor Therapeutics, Inc., while simultaneously disclosing substantial doubt about its ability to continue as a going concern and seeking an extension for its business combination deadline.

Summary

• Black Hawk Acquisition Corporation (Black Hawk), a blank check company, reported its financial results for the three and six months ended May 31, 2025.
• The company has entered into a Business Combination Agreement with Vesicor Therapeutics, Inc., an early development stage biotechnology corporation, on April 26, 2025.
• The proposed transaction values Vesicor at a pre-money equity value of $70 million, with existing Vesicor shareholders and management rolling over 100% of their equity.
• Black Hawk's net income significantly increased to $520,542 for the three months ended May 31, 2025, up from $310,936 in the prior year period.
• For the six months ended May 31, 2025, net income was $1,178,921, a substantial increase from $280,235 in the same period last year.
• Interest earned on investments held in the Trust Account was a primary driver of income, reaching $767,623 for the three months and $1,533,534 for the six months ended May 31, 2025.
• The company's cash balance decreased to $72,914 as of May 31, 2025, from $264,842 as of November 30, 2024.
• A working capital deficit of $111,520 was reported as of May 31, 2025.
• Management has determined that conditions raise substantial doubt about the company's ability to continue as a going concern.
• The company is seeking to extend its business combination deadline from June 22, 2025, to December 22, 2026, through an Extension Proposal requiring shareholder approval.
• Changes in the Board of Directors were reported, including the passing of a board member and subsequent reassignments of committee chairpersons.

Sentiment

Score: 4

Explanation: While the company has secured a business combination target and shown improved net income due to trust account interest, the significant 'going concern' warning, working capital deficit, and ineffective internal controls, coupled with the need for a deadline extension and the high-risk nature of the target's industry, indicate considerable operational and financial uncertainty. The positive aspects are overshadowed by fundamental solvency and control issues.

Positives

• Net income significantly increased to $520,542 for the three months ended May 31, 2025, compared to $310,936 for the same period in 2024.
• Net income for the six months ended May 31, 2025, was $1,178,921, a substantial improvement from $280,235 in the prior year period.
• Interest income from the Trust Account increased, contributing $767,623 for the three months and $1,533,534 for the six months ended May 31, 2025.
• A definitive Business Combination Agreement has been signed with Vesicor Therapeutics, Inc., valuing Vesicor at a pre-money equity value of $70 million, indicating progress towards a de-SPAC transaction.
• Vesicor's existing shareholders and management are rolling over 100% of their equity into the combined company, demonstrating commitment to the merger.

Negatives

• The company has a working capital deficit of $111,520 as of May 31, 2025.
• Cash balance significantly decreased to $72,914 as of May 31, 2025, from $264,842 as of November 30, 2024.
• Management has determined that conditions raise substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures were deemed not effective as of May 31, 2025.
• The company is incurring significant professional and transaction costs as a publicly traded company and in pursuit of a Business Combination.
• The passing of a board member and Audit Committee Chairperson, Brandon Miller, represents a loss to the board.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to working capital deficit and uncertainty of completing a Business Combination within the Combination Period.
• Failure to complete a Business Combination within the Combination Period (15 months, extendable to 21 months) would lead to liquidation and redemption of public shares.
• The company's ability to consummate a Business Combination or the operations of a target business may be materially and adversely affected by various social and political circumstances, including rising trade tensions and ongoing global conflicts (Russia/Ukraine, Hamas/Israel).
• The ability to raise equity and debt financing may be impacted by increased market volatility or decreased market liquidity, potentially making third-party financing unavailable on acceptable terms.
• The per share value of assets remaining for distribution could be less than $10.05 if the company liquidates.
• The Sponsor's liability for claims reducing the Trust Account below $10.05 per Public Share has exceptions, meaning public shareholders could still face losses.
• Inherent limitations on the effectiveness of internal controls mean that misstatements due to error or fraud may occur and not be detected.
• The target company, Vesicor Therapeutics, Inc., is an early development stage biotechnology corporation, which inherently carries high risks associated with drug development and regulatory approvals.

Future Outlook

Black Hawk Acquisition Corporation expects to complete its business combination with Vesicor Therapeutics, Inc. by the fourth quarter of 2025, subject to regulatory and shareholder approvals, and Nasdaq listing approval. The company anticipates incurring significant professional and transaction costs in pursuit of this combination and expects to generate non-operating income from interest on its Trust Account investments until the business combination is completed. The company is also seeking an extension of its business combination deadline to December 22, 2026, to allow more time for the transaction.

Management Comments

• "We have neither engaged in any operations nor generated any revenues to date. Our only activities from September 28, 2023 (inception) through May 31, 2025, were organizational activities and those necessary to consummate the IPO, and subsequent to the IPO, identifying a target company for an initial business combination."
• "We expect to continue to incur significant costs in the pursuit of our acquisition plans."
• "Management has determined that these conditions [working capital deficit, need for additional capital, and uncertainty of completing a Business Combination within the Combination Period] raise substantial doubt about the Company’s ability to continue as a going concern."
• "Our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective at a reasonable assurance level as of May 31, 2025."

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) nearing its business combination deadline. The proposed merger with Vesicor Therapeutics, an early-stage biotechnology company focused on p53-based cancer therapeutics, aligns with a broader trend of SPACs targeting innovative, high-growth sectors like biotech. The significant increase in interest income reflects the current higher interest rate environment, which benefits SPACs holding substantial funds in trust accounts. However, the disclosed 'going concern' risk is a common challenge for SPACs that face difficulties in identifying or closing a suitable business combination within their initial timeframe, often leading to extension requests and potential redemptions, which can reduce the capital available for the de-SPAC transaction. The need for an extension and the internal control deficiencies highlight operational challenges that can impact investor confidence in the SPAC model.

Comparison to Industry Standards

• The pre-money equity valuation of $70 million for Vesicor Therapeutics, an early-stage biotechnology company, is within the typical range for private biotech firms seeking to go public via SPAC, though specific comparable companies or projects are not detailed in the filing.
• The increase in interest income from the Trust Account is consistent with the general market trend of higher interest rates on short-term U.S. government securities, which benefits SPACs holding large cash reserves.
• The disclosure of 'substantial doubt about the company's ability to continue as a going concern' and the need for an extension are common challenges for SPACs that have not completed a business combination within their initial timeframe, reflecting the inherent time pressure and execution risk in the SPAC model. Many SPACs, such as Gores Holdings VI (GHVI) or Churchill Capital Corp IV (CCIV) before their respective mergers, faced similar pressures and sought extensions.
• The identified ineffectiveness of disclosure controls and procedures is a significant governance concern that deviates from best practices for publicly traded companies, regardless of industry, and could raise red flags for investors and regulators. This is a specific internal control weakness, not an industry-wide standard.

Management Changes

Corporate Governance

Related Party Transactions

• Administrative Services Agreement with Black Hawk Management LLC (the Sponsor) for $10,000 per month for office space and administrative services. The Company incurred $30,000 for the three months and $60,000 for the six months ended May 31, 2025.
• The Sponsor loaned the Company $250,000 under an unsecured promissory note, which was repaid on March 25, 2024.
• Initial Shareholders or their affiliates may, but are not obligated to, loan the Company funds for transaction costs in connection with an intended initial Business Combination.

Stakeholder Impact

• **Shareholders:** Face uncertainty regarding the completion of the business combination and the company's ability to continue as a going concern. The proposed extension and its terms directly impact their investment timeline and potential redemption value. The ineffectiveness of internal controls could also impact confidence.
• **Employees (future, of combined entity):** The successful completion of the merger with Vesicor would secure their employment and future prospects within the combined entity.
• **Vesicor Therapeutics, Inc. (Target Company):** The merger provides a path to public listing and access to capital, but the ongoing SPAC uncertainties and extension process could create delays or complications for their strategic plans.
• **Sponsor (Black Hawk Management LLC):** Bears the financial burden of extension contributions ($0.033 per public share per month) to keep the SPAC alive, and has agreed to waive liquidation rights on Founder Shares if a business combination is not completed. Also liable for certain claims reducing the Trust Account.
• **Underwriters (EF Hutton):** Entitled to a deferred fee of $2,415,000 upon the closing of a Business Combination, which is contingent on the merger's success.

Next Steps

• Shareholders to vote on the Extension Proposal at the extraordinary general meeting, currently adjourned to June 27, 2025.
• If the Extension Proposal is approved, the Sponsor or its affiliates will deposit $0.033 per public share into the Trust Account for each one-month extension.
• Black Hawk Acquisition Corporation will de-register in the Cayman Islands and domesticate as a Delaware corporation.
• Vesicor Therapeutics, Inc. will reincorporate into the State of Delaware.
• Merger Sub will merge with Vesicor, with Vesicor becoming a wholly owned subsidiary of the Company.
• The combined company will change its name to Vesicor and continue to be listed on the Nasdaq Stock Market.
• Completion of the Business Combination is expected by the fourth quarter of 2025, subject to regulatory approvals, shareholder approvals, and Nasdaq listing approval.

Key Dates

Recommendation

Keywords

SPAC, Special Purpose Acquisition Company, Business Combination, Merger, Vesicor Therapeutics, Biotechnology, Cancer Therapeutics, SEC Filing, 10-Q, Financial Results, Going Concern, Trust Account, Extension Proposal, Corporate Governance, Nasdaq